186 related articles for article (PubMed ID: 29994951)
1. Estimation of Prognosis in Invasive Cutaneous Melanoma: An Independent Study of the Accuracy of a Gene Expression Profile Test.
Greenhaw BN; Zitelli JA; Brodland DG
Dermatol Surg; 2018 Dec; 44(12):1494-1500. PubMed ID: 29994951
[TBL] [Abstract][Full Text] [Related]
2. Identification of high-risk cutaneous melanoma tumors is improved when combining the online American Joint Committee on Cancer Individualized Melanoma Patient Outcome Prediction Tool with a 31-gene expression profile-based classification.
Ferris LK; Farberg AS; Middlebrook B; Johnson CE; Lassen N; Oelschlager KM; Maetzold DJ; Cook RW; Rigel DS; Gerami P
J Am Acad Dermatol; 2017 May; 76(5):818-825.e3. PubMed ID: 28110997
[TBL] [Abstract][Full Text] [Related]
3. Identification of patients at risk of metastasis using a prognostic 31-gene expression profile in subpopulations of melanoma patients with favorable outcomes by standard criteria.
Gastman BR; Gerami P; Kurley SJ; Cook RW; Leachman S; Vetto JT
J Am Acad Dermatol; 2019 Jan; 80(1):149-157.e4. PubMed ID: 30081113
[TBL] [Abstract][Full Text] [Related]
4. Interim analysis of survival in a prospective, multi-center registry cohort of cutaneous melanoma tested with a prognostic 31-gene expression profile test.
Hsueh EC; DeBloom JR; Lee J; Sussman JJ; Covington KR; Middlebrook B; Johnson C; Cook RW; Slingluff CL; McMasters KM
J Hematol Oncol; 2017 Aug; 10(1):152. PubMed ID: 28851416
[TBL] [Abstract][Full Text] [Related]
5. Performance of a prognostic 31-gene expression profile in an independent cohort of 523 cutaneous melanoma patients.
Zager JS; Gastman BR; Leachman S; Gonzalez RC; Fleming MD; Ferris LK; Ho J; Miller AR; Cook RW; Covington KR; Meldi-Plasseraud K; Middlebrook B; Kaminester LH; Greisinger A; Estrada SI; Pariser DM; Cranmer LD; Messina JL; Vetto JT; Wayne JD; Delman KA; Lawson DH; Gerami P
BMC Cancer; 2018 Feb; 18(1):130. PubMed ID: 29402264
[TBL] [Abstract][Full Text] [Related]
6. Prospective validation of the prognostic 31-gene expression profiling test in primary cutaneous melanoma.
Keller J; Schwartz TL; Lizalek JM; Chang ES; Patel AD; Hurley MY; Hsueh EC
Cancer Med; 2019 May; 8(5):2205-2212. PubMed ID: 30950242
[TBL] [Abstract][Full Text] [Related]
7. Validation of a 40-gene expression profile test to predict metastatic risk in localized high-risk cutaneous squamous cell carcinoma.
Wysong A; Newman JG; Covington KR; Kurley SJ; Ibrahim SF; Farberg AS; Bar A; Cleaver NJ; Somani AK; Panther D; Brodland DG; Zitelli J; Toyohara J; Maher IA; Xia Y; Bibee K; Griego R; Rigel DS; Meldi Plasseraud K; Estrada S; Sholl LM; Johnson C; Cook RW; Schmults CD; Arron ST
J Am Acad Dermatol; 2021 Feb; 84(2):361-369. PubMed ID: 32344066
[TBL] [Abstract][Full Text] [Related]
8. 31-Gene Expression Profile Testing in Cutaneous Melanoma and Survival Outcomes in a Population-Based Analysis: A SEER Collaboration.
Bailey CN; Martin BJ; Petkov VI; Schussler NC; Stevens JL; Bentler S; Cress RD; Doherty JA; Durbin EB; Gomez SL; Gonsalves L; Hernandez BY; Liu L; Morawski BM; Schymura MJ; Schwartz SM; Ward KC; Wiggins C; Wu XC; Goldberg MS; Siegel JJ; Cook RW; Covington KR; Kurley SJ
JCO Precis Oncol; 2023 Jun; 7():e2300044. PubMed ID: 37384864
[TBL] [Abstract][Full Text] [Related]
9. The 31-gene expression profile stratifies recurrence and metastasis risk in patients with cutaneous melanoma.
Jarell A; Skenderis B; Dillon LD; Dillon K; Martin B; Quick AP; Siegel JJ; Rackley BB; Cook RW
Future Oncol; 2021 Dec; 17(36):5023-5031. PubMed ID: 34587770
[TBL] [Abstract][Full Text] [Related]
10. Enhanced metastatic risk assessment in cutaneous squamous cell carcinoma with the 40-gene expression profile test.
Ibrahim SF; Kasprzak JM; Hall MA; Fitzgerald AL; Siegel JJ; Kurley SJ; Covington KR; Goldberg MS; Farberg AS; Trotter SC; Reed K; Brodland DG; Koyfman SA; Somani AK; Arron ST; Wysong A
Future Oncol; 2022 Mar; 18(7):833-847. PubMed ID: 34821148
[TBL] [Abstract][Full Text] [Related]
11. Molecular risk prediction in cutaneous melanoma: A meta-analysis of the 31-gene expression profile prognostic test in 1,479 patients.
Greenhaw BN; Covington KR; Kurley SJ; Yeniay Y; Cao NA; Plasseraud KM; Cook RW; Hsueh EC; Gastman BR; Wei ML
J Am Acad Dermatol; 2020 Sep; 83(3):745-753. PubMed ID: 32229276
[TBL] [Abstract][Full Text] [Related]
12. Association between traditional clinical high-risk features and gene expression profile classification in uveal melanoma.
Nguyen BT; Kim RS; Bretana ME; Kegley E; Schefler AC
Graefes Arch Clin Exp Ophthalmol; 2018 Feb; 256(2):421-427. PubMed ID: 29185101
[TBL] [Abstract][Full Text] [Related]
13. Management Decisions Made by Physician Assistants and Nurse Practitioners in Cutaneous Malignant Melanoma Patients: Impact of a 31-Gene Expression Profile Test.
Mirsky R; Prado G; Svoboda R; Glazer A; Rigel D
J Drugs Dermatol; 2018 Nov; 17(11):1220-1223. PubMed ID: 30500144
[TBL] [Abstract][Full Text] [Related]
14. Long-Term Outcomes in a Multicenter, Prospective Cohort Evaluating the Prognostic 31-Gene Expression Profile for Cutaneous Melanoma.
Hsueh EC; DeBloom JR; Lee JH; Sussman JJ; Covington KR; Caruso HG; Quick AP; Cook RW; Slingluff CL; McMasters KM
JCO Precis Oncol; 2021; 5():. PubMed ID: 34036233
[TBL] [Abstract][Full Text] [Related]
15. Integration of a 31-Gene Expression Profile Into Clinical Decision-Making in the Treatment of Cutaneous Melanoma.
Scott AM; Dale PS; Conforti A; Gibbs JN
Am Surg; 2020 Nov; 86(11):1561-1564. PubMed ID: 32755379
[TBL] [Abstract][Full Text] [Related]
16. The 31-Gene Expression Profile Test Outperforms AJCC in Stratifying Risk of Recurrence in Patients with Stage I Cutaneous Melanoma.
Podlipnik S; Martin BJ; Morgan-Linnell SK; Bailey CN; Siegel JJ; Petkov VI; Puig S
Cancers (Basel); 2024 Jan; 16(2):. PubMed ID: 38254778
[TBL] [Abstract][Full Text] [Related]
17. Frequency and implications of discordant gene expression profile class in posterior uveal melanomas sampled by fine needle aspiration biopsy.
Augsburger JJ; Corrêa ZM; Augsburger BD
Am J Ophthalmol; 2015 Feb; 159(2):248-56. PubMed ID: 25448994
[TBL] [Abstract][Full Text] [Related]
18. Primary dermal melanoma: a unique subtype of melanoma to be distinguished from cutaneous metastatic melanoma: a clinical, histologic, and gene expression-profiling study.
Sidiropoulos M; Obregon R; Cooper C; Sholl LM; Guitart J; Gerami P
J Am Acad Dermatol; 2014 Dec; 71(6):1083-92. PubMed ID: 25262174
[TBL] [Abstract][Full Text] [Related]
19. Identification of stage I/IIA melanoma patients at high risk for disease relapse using a clinicopathologic and gene expression model.
Eggermont AMM; Bellomo D; Arias-Mejias SM; Quattrocchi E; Sominidi-Damodaran S; Bridges AG; Lehman JS; Hieken TJ; Jakub JW; Murphree DH; Pittelkow MR; Sluzevich JC; Cappel MA; Bagaria SP; Perniciaro C; Tjien-Fooh FJ; Rentroia-Pacheco B; Wever R; van Vliet MH; Dwarkasing J; Meves A
Eur J Cancer; 2020 Nov; 140():11-18. PubMed ID: 33032086
[TBL] [Abstract][Full Text] [Related]
20. Attitudes of patients with cutaneous melanoma toward prognostic testing using the 31-gene expression profile test.
Ahmed K; Siegel JJ; Morgan-Linnell SK; LiPira K
Cancer Med; 2023 Jan; 12(2):2008-2015. PubMed ID: 35915969
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
